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Background. Kawasaki disease (KD) is characterized by systemic vasculitis of unknown etiology. Our previous studies showed
expression of CD40 ligand on CD4+ T cells correlated to the coronary artery lesion (CAL) and disease progress in KD. Other
studies from Japan suggested the role of CD40L in the pathogenesis of CAL, and this might help explain the excessive number of
males aﬀected with KD but cannot be reproduced by Taiwanese population. This study was conducted to investigate the CD40
polymorphism in KD and CAL formation. Methods. A total of 950 subjects (381KD patients and 569 controls) were investigated
to identify 2 tagging single-nucleotide polymorphisms (tSNPs) of CD40 (rs4810485 and rs1535045) by using the TaqMan allelic
discriminationassay.Results.AsigniﬁcantassociationwasnotedwithregardstoCD40tSNPs(rs1535045)betweencontrolsandKD
patients (P = 0.0405, dominant model). In KD patients, polymorphisms of CD40 (rs4810485) showed signiﬁcant association with
CAL formation (P = 0.0436, recessive model). Haplotype analysis did not yield more signiﬁcant results between polymorphisms
of CD40 and susceptibility/disease activity of KD. Conclusions. This study showed for the ﬁrst time that polymorphisms of CD40
are associated with susceptibility to KD and CAL formation, in the Taiwanese population.
1.Introduction
Kawasaki disease (KD) is characterized by acute, febrile, sys-
temic vasculitis and was ﬁrst described by Kawasaki et al. in
1974 [1]. The most serious complication of KD is the occur-
rence of coronary artery lesions (CALs) [2]. In developed
countries, KD is the leading cause of acquired heart diseases
in children. KD primarily aﬀects children less than 5 years of
age [3], and the prevalence is highest in Japan, followed by
Korea and Taiwan, and lowest in Europe [4].
TheetiologyofKDisstillunderinvestigation.Esperetal.
reported that human coronavirus is associated with KD but
cannot be reproduced by other groups [5]. Previous studies
have either failed to identify the causative pathogen for KD
or reported discrepant results [5–7]. Evidence suggests that
immune activation with vascular endothelial inﬂammation2 The Scientiﬁc World Journal
may be involved in the pathogenesis of KD and CAL for-
mation. Acute stage of KD is reported to be associated with
overactivation of immunologic factors including immune-
competent cell activation [4], cytokines [8, 9], nitric oxide
production [10], autoantibody production [11, 12], and ad-
hesion molecule expression [13, 14].
CD40 ligand (CD40L, CD154, gp 39), a transmem-
brane protein structurally related to tumor necrosis factor-
alpha, was originally identiﬁed on activated CD4+ T cells.
Both membrane-bound and soluble forms of CD40L may
interact with CD40, which is mainly expressed on B cells,
macrophages, endothelial cells, and vascular smooth mus-
cle cells, resulting in various immune and inﬂammatory
responses [15, 16]. Interaction between CD40L and CD40
plays a central role in the activation of the immune system,
such as immunoglobulin G (IgG) switching, autoimmune
disease, antiviral eﬀect, allograft rejection, cytokines regu-
lation, arthrosclerosis, and endothelial cell interaction [17,
18]. CD40-CD40L system is also associated with both pro-
thrombotic and proinﬂammatory eﬀects [19, 20]. The solu-
ble form of CD40L (sCD40L) is derived mainly from acti-
vated platelets and contributes to the pathophysiology of
atherosclerosis and atherothrombosis [20]. Indeed, sCD40L
has autocrine, paracrine, and endocrine activities, and it
enhances platelet activation, aggregation, and platelet-leuco-
cyte conjugation that may lead to atherothrombosis. It also
has been suggested that sCD40L may play a pathogenic role
in triggering acute coronary syndromes [19]. By detecting
expression level of CD40L from clinical samples, our previ-
ousstudyprovidesevidencethatsupportsafunctionalroleof
CD40L in the susceptibility of KD and CAL formation [21].
Several reports have indicated that genetic polymor-
phismsmaycontributetothesusceptibilityanddiseasesever-
ity of KD. For example, polymorphisms in the genes includ-
ing IL-10, CASP3, IL-18, and inositol 1,4,5-trisphosphate
3-kinase C (ITPKC)h a v eb e e nr e p o r t e dt ob ei n v o l v e di n
the development of KD [22–26]. In 2004, Onouchi and
colleagues were the ﬁrst group reporting the association
between CD40L gene polymorphisms and KD [27]. Our
previous studies have shown that expression of CD40L on
CD4+ T cells was correlated to the coronary artery lesion
(CAL) and disease progress in KD [21]. However, another
group from Taiwan reported the lack of an association
between CD40L polymorphisms and susceptibility KD in
a Taiwanese population [28]. Therefore, we strived to
investigate the potential genetic role of CD40 in the suscep-
tibility of KD and CAL formation in the Taiwanese popula-
tion.
2.MaterialandMethods
2.1. Patients Studied. A l ls u b j e c t ss t u d i e dw e r ec h i l d r e n
who ﬁlled the diagnostic criteria for KD according to 2004
AHA criteria [29] and were admitted to the Kaohsiung
Chang Gung Memorial Hospital between 2000 and 2010.
All patients were treated with a single infusion of IVIG
(2g/kg) administered over a 12-hour period. Aspirin was
administered until all signs of inﬂammation were resolved
or regression of CAL was detected under two-dimensional
(2D) echocardiography as in our previous reports [30–32].
This study was approved by the Institutional Review Board
of the Chang Gung Memorial Hospital. CAL was deﬁned by
the internal diameter of the coronary artery being at least
3mm (or 4mm if the subject was over the age of 5 years)
or the internal diameter of a segment being at least 1.5 times
of an adjacent segment in the echocardiogram [22, 33]. IVIG
responsiveness was deﬁned as defervescence within 48 hours
after the completion of IVIG treatment and being without
fever (temperature, >38◦C) [2, 34].
2.2. DNA Extraction. B l o o dc e l l sw e r es u b j e c t e dt oD N A
extraction by treating them ﬁrst with 0.5% SDS lysis buﬀer
and then protease K (1mg/mL) for digestion of nuclear
protein for 4h at 60◦C. Using the Gentra extraction kit
followed by 70% alcohol precipitation, total DNA was har-
vested.
2.3. Genotyping. Two tagging SNPs (rs4810485 and
rs1535045) in the CD40 gene with a minor allele frequency
of >10% in the Han Chinese population were selected from
the HapMap database (http://www.hapmap.org/). Genotyp-
ing was performed by using the TaqMan allelic discrimina-
tion assay (Applied Biosystems, Foster city, CA, USA) was
noted in our previous report [22, 24, 35]. Brieﬂy, PCR prim-
ers and TaqMan minor groove binding probes were designed
byappliedBiosystems.Thepolymerasechainreaction(PCR)
was carried out in a 96-well microplate with the ABI 9700
Thermal Cycler. After PCR, ﬂuorescence was detected by ABI
7500 Real-Time PCR system and data was analyzed using
the System SDS software (version 1.2.3).
2.4. Statistical Analysis. JMP 9.0 for Windows was used for
analysis. The statistical diﬀerences between case and control
in genotype and allele frequency were assessed by the χ2-test.
Statistical diﬀerences in genotype and allele frequency of KD
patients with/without CAL formation were assessed using
the χ2 test. Linkage disequilibrium (LD) was assessed for
one pair of SNPs, and haplotype blocks were deﬁned using
the default setting of the Haploview software 4.1 (Broad
Institute, Cambridge, MA, USA).
3. Results
3.1. A Signiﬁcant Association between Genetic Polymorphisms
in CD40 and Susceptibility to Kawasaki Disease. At o t a lo f
950 subjects including 381 KD patients and 569 controls
were recruited in this study. Table 1 shows the characteristics
of the subjects. The average age of cases was 1.7 years and
that in the controls is 5.7 years. CAL was observed in 9.7%
(37/381) of KD patients 8 weeks after disease onset, and
12.9% (49/381) of the KD patients were resistant to initial
IVIG treatment. The genotype frequencies of the controls
and patients were in the Hardy-Weinberg equilibrium (Table
2). Polymorphism rs1535045 in the CD40 was found to have
signiﬁcant inﬂuence with regards to the susceptibility of KD
(P = 0.0405).The Scientiﬁc World Journal 3
Table 1: Basal characteristics of patients with Kawasaki disease and normal controls.
Characteristics Patients with KD Normal control
N = 381 N = 569
Mean (SD) age (years) 1.7 ±1.65 .7 ± 4.9
Age range (years) 0–11 0–51
CAL formation 37 (9.7%)
IVIG resistance 49 (12.9%)
CAL: coronary artery lesions; IVIG: intravenous immunoglobulin; SD: standard deviation.
Table 2: Genotype and allele frequencies of the CD40 gene in controls and patients with Kawasaki disease.
Genotype Case (%)
(n = 381)
Control (%)
(n = 569) Allele Case (%)
(n = 381)
Control (%)
(n = 569)
Genotype
P value
Dominant
P value
Recessive
P value
Allelic
P value
rs4810485
TT 50 (13.2) 99 (17.7) T 284 (37.4) 460 (41.1) 0.1632 0.3489 0.0609 0.1005
GT 184 (48.4) 262 (46.9) G 476 (62.6) 658 (58.9)
GG 146 (38.4) 198 (35.4)
rs1535045
TT 44 (11.5) 61 (10.8) T 262 (34.4) 346 (30.6) 0.1160 0.0405∗ 0.7180 0.0856
CT 174 (45.7) 224 (39.6) C 500 (65.6) 784 (69.4)
CC 163 (42.8) 280 (49.6)
∗Signiﬁcant (P<0.05) values are in bold.
Table 3: Genotype and allele frequencies of the CD40 gene in patients with or without coronary artery lesion (CAL) formation.
Genotype CAL (%)
(n = 37)
Without (%)
(n = 336) Allele CAL (%)
(n = 37)
Without (%)
(n = 336)
Genotype
P value
Dominant
P value
Recessive
P value
Allelic
P value
rs4810485
TT 1 (2.7) 49 (14.6) T 25 (33.8) 253 (37.8) 0.0666 0.6381 0.0436∗ 0.5021
GT 23 (62.2) 155 (46.3) G 49 (66.2) 417 (62.2)
GG 13 (35.1) 131 (39.1)
rs1535045
TT 2 (5.4) 41 (12.2) T 23 (31.1) 233 (34.7) 0.4410 0.9641 0.2192 0.5368
CT 19 (51.4) 151 (44.9) C 51 (68.9) 439 (65.3)
CC 16 (43.2) 144 (42.9)
∗Signiﬁcant (P<0.05) values are in bold.
Table 4: Haplotype frequencies of the CD40 gene in controls and patients with Kawasaki disease.
rs4810485/rs1535045 Case (%)
(n = 381)
Control (%)
(n = 569) OR (95% CI) P Value
G/T 258 (34.0) 343 (30.7) 1.22 (0.98–1.52) 0.0767
G/C 216 (28.5) 317 (28.3) 1.10 (0.88–1.39) 0.3937
T/C 282 (37.2) 457 (40.8) Reference
Haplotype frequency less than 1% was excluded.
3.2. CD40 Genetic Polymorphisms Associated with CAL For-
mation in the KD Patients. The association between CD40
genotypes and CAL formation, the major complication of
KD, was evaluated. 37 patients among the 381KD patients
developed CAL. Our results indicated that the TT genotype
of rs4810485 has protective eﬀects for CAL formation in KD
patients (Table 3).
3.3. Haplotype Analysis of CD40 in the KD Patients. We
further calculated pairwise linkage disequilibrium (LD)
and analyzed haplotypes of CD40. However, no signiﬁcant
association was found between CD40 haplotype analysis and
the susceptibility of KD (Table 4), as well as CAL formation
(Table 5).
4. Discussion
Kawasaki disease is caused by activation of the immune
system targeting on vascular endothelium, resulting in
systemicvasculitisorevencoronaryarterylesionsformation.
Interaction of CD40L with its receptor CD40 has been
implicated in the modulation of immune and inﬂammatory
responses, which are critical for the activation of tissue
structure cells, such as endothelial cells, smooth muscle4 The Scientiﬁc World Journal
Table 5: Haplotype frequencies of the CD40 gene in patients with or without coronary artery lesion formation.
rs4810485/rs1535045 CAL (%)
(n = 37)
Without (%)
(n = 336) OR (95% CI) P value
G/T 23 (31.1) 231 (34.5) 1.00 (0.55–1.81) 0.9991
G/C 26 (35.1) 186 (27.8) 1.40 (0.79–2.51) 0.2511
T/C 25 (33.8) 251 (37.5) Reference
cells, epithelial cells, and ﬁbroblast and induce produc-
tion of a cascade of proinﬂammatory cytokines [18, 19].
The CD40-CD40L signaling pathway has been associated
with the pathogenic processes of chronic inﬂammatory
diseases, including autoimmune diseases, neurodegenerative
disorders, graft-versus-host disease, cancer, vasculitis, and
atherosclerosis [17, 20]. In the presented study, our results
implied that genetic polymorphisms in CD40 may result in
the overactivation of proinﬂammatory signaling pathways
that lead to the development of KD.
Our previous report indicated that expression of CD40L
on CD4+ T-cells correlated to the CAL formation and dis-
ease progress in KD patients [21]. Burns and Glod´ e also
suggested that CD40-CD40L interaction impacts on the vas-
culitis pathogenesis of KD [4]. Therefore, the CD40-CD40L
signaling pathway may play an important pathogenic role in
acute coronary syndromes such as the CAL of patients with
KD.Inthisstudy,wefoundthatCD40geneticpolymorphism
(rs1535045) is associated with susceptibility of KD. Inter-
estingly, rs1535045 in CD40 gene has been conﬁrmed to be
associated with the coronary artery calciﬁcation in diabetic
families [36]. These observations in combination with those
of the present study support genetic polymorphism eﬀects of
CD40 in the vascular diseases. Further study into the mech-
anisms between CD40-CD40L interaction and long-term
coronary arterial vasculitis may provide a better understand-
ing for the pathogenesis of KD.
Althoughourstudiesindicatedthesigniﬁcantassociation
between genetic polymorphisms of CD40 and the risk of
KD, haplotypes of KD didn not yield signiﬁcant results. We
acknowledged that the modest sample size in the study was
underpowered to detect the small genetic eﬀect of CD40 in
the disease severity such as CAL formation. These ﬁndings
need to be replicated in a second population with a larger
sample size.
Taken together, our results indicated that the genetic
polymorphisms of CD40 are very likely to be involved in the
susceptibility and disease severity of KD in a Taiwanese pop-
ulation.
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